Document:

Exhibit 10.1

      

      

      REGISTRATION RIGHTS AGREEMENT

      

      

      This Registration Rights Agreement (this “Agreement”) is made and entered into as of
        December 28, 2022, between Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.) a Delaware corporation, and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser”
        and, collectively, the “Purchasers”).

      

      

      WHEREAS, the Company is party to that certain Agreement and Plan of Merger and Reorganization by and among the Company, Gemstone Merger Sub, Inc.,
        Gemini Therapeutics, Inc. (“Gem”), dated as of August 9, 2022 (the “Merger Agreement”), pursuant to which the Company will
        become a wholly-owned subsidiary of Gem (the “Merger”);

      

      

      WHEREAS, following the Merger (as defined in the Merger Agreement), Gem will change its name to Disc Medicine, Inc. (“TopCo”);

      

      

      WHEREAS, the Company and the Purchasers are parties to a Subscription Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Purchasers, severally and not jointly, are purchasing shares of Common Stock of the Company (the “Purchased Shares”);
        and

       

        

      WHEREAS, in connection with the consummation of the transactions contemplated by the Purchase Agreement, and pursuant to the terms of the Purchase
        Agreement, the parties desire to enter into this Agreement in order to grant certain rights to the Purchasers as set forth below.

       

        

      NOW, THEREFORE, in consideration of the covenants and promises set forth herein, and for other good and valuable consideration, the receipt and
        sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

      

      

      The Company and each Purchaser hereby agree as follows:

      

      

      	

            	1.	
              Definitions.

            

      

      

      Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
        Purchase Agreement.

      As used in this Agreement, the following terms shall have the following meanings:

      

      

      “Advice” shall have the meaning set forth in Section 6(c).

      

      

      “Company” means Disc Medicine Opco, Inc. (f/k/a Disc Medicine, Inc.)
        for all periods prior to closing of the Merger and TopCo for all periods after completion of the Merger.

      

      

      “Effectiveness Date” means, with respect to the Initial Registration
        Statement required to be filed hereunder, the 90th calendar day following the date hereof (or, in the event of a “full review” by the Commission, the 120th calendar day following the date hereof) and with respect to any
        additional Registration Statements that may be required pursuant to Sections 2(b) and 2(c) or Section 3(c), the 60th calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or, in
        the event of a “full review” by the Commission, the 90th calendar day following the date thereof); provided, however,
        that in the event the Company is notified by the Commission (orally or in writing) that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such
        Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a
        Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.

      

      

      
        
          

      

      “Effectiveness Period” shall have the meaning set forth in Section
        2(a).

      

      

      “Filing Date” means, with respect to the Initial Registration
        Statement required hereunder, the 45th calendar day following the date hereof and, with respect to any additional Registration Statements that may be required pursuant to Sections 2(b) and 2(c) or Section 3(c), the earliest practical
        date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.

      

      

      “Holder” or “Holders”
        means the holder or holders, as the case may be, from time to time of Registrable Securities.

      

      

      “Indemnified Party” shall have the meaning set forth in Section 5(c).

      

      

      “Indemnifying Party” shall have the meaning set forth in Section
        5(c).

      

      

      “Initial Registration Statement” means the initial Registration
        Statement filed pursuant to this Agreement.

      

      

      “Losses” shall have the meaning set forth in Section 5(a).

      

      

      “Plan of Distribution” shall have the meaning set forth in Section
        2(a).

      

      

      “Prospectus” means the prospectus included in a Registration
        Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the
        Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the
        Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

      

      

      “Registrable Securities” means, as of any date of determination, (a)
        all shares of Gem common stock issued to the Purchasers at the closing of the Merger in respect of the Purchased Shares (the “Purchase Agreement Shares”), (b) all shares of Gem issued at
        the closing of the Merger to the Purchasers in respect of all other shares of capital stock of the Company held by Purchaser as of immediately prior to the Effective Time (as defined in the Merger Agreement), and (c) all shares of Gem held by
        Purchaser as of immediately prior to the Effective Time,  (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration
        Statement hereunder with respect thereto) upon the earliest to occur of (i) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable
        Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (ii) such Registrable Securities have been previously sold in accordance with Rule 144, (iii) such securities become eligible for resale
        without volume or manner-of-sale restrictions  pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by counsel to the Company pursuant to
        a written opinion letter to such effect, addressed, delivered and acceptable to the Company’s transfer agent and the affected Holders, and (iv) five years after the date of this Agreement.

      

      

      
        
          

      

      “Registration Statement” means any registration statement required to
        be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or
        Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.

      

      

      “Rule 415” means Rule 415 promulgated by the Commission pursuant to
        the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

      

      

      “Rule 424” means Rule 424 promulgated by the Commission pursuant to
        the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

      

      

      “SEC Guidance” means (i) any publicly-available written or oral
        guidance of the Commission staff, or any comments, requirements or requests of the Commission staff; provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the Commission and (ii) the Securities Act.

      

      

      “Selling Stockholder Questionnaire” shall have the meaning set forth
        in Section 3(a).

      

      

      “Trading Day” means any day on which the Gem Common Stock is traded
        on a National Exchange.

      

      

      
        	 	
                2.

                

              	
                Shelf Registration.

              

      

      

      

      (a) On or prior to each Filing Date, the Company shall (or shall cause TopCo to) prepare and file with the Commission a
        Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement
        filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith, subject to
        the provisions of Section 2(d)) and shall contain (unless otherwise directed by at least 85% in interest of the Holders) disclosure substantially in the form of the “Plan of Distribution”
        attached hereto as Annex A and substantially in the form of the “Selling Stockholder” section attached hereto as Annex B. Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration Statement filed under this Agreement (including, without limitation,
        under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its reasonable best efforts to keep such
        Registration Statement continuously effective under the Securities Act until the earlier of (a) the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be
        sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company
        pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders and (b) five years after the date of this Agreement (the “Effectiveness

            Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall promptly notify the Holders via facsimile or by e-mail of the
        effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by
        9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.

      

      

      
        
          

      

      (b) Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the
        Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its reasonable
        best efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to
        register for resale the Registrable Securities as a secondary offering; with respect to filing on Form S-3 or other appropriate form; provided, however, that prior to filing such amendment, the Company shall be obligated to use commercially reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance
        with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.

      

      

      (c) Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the
        number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used reasonable efforts to advocate with the Commission for the registration of all or
        a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the total number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:

      

      

      	 	a.	
              First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities;

            

      	

            	b.	
              Second, the Company shall reduce Registrable Securities represented by Shares other than the Purchase Agreement Shares (applied, in the case that some of such Shares may be
                registered, to the Holders on a pro rata basis based on the total number of such unregistered Shares held by such Holders); and

            

      	

            	c.	
              Third, the Company shall reduce Registrable Securities represented by the Purchase Agreement Shares (applied, in the case that some Purchase Agreement Shares may be registered,
                to the Holders on a pro rata basis based on the total number of unregistered Purchase Agreement Shares held by such Holders)

            

      

      

      In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the
        calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as
        allowed by the Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were
        not registered for resale on the Initial Registration Statement, as amended.

      

      

      
        
          

      

      (d) If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i)
        register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the
        Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.

      

      

      (e) Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or
        affiliate of a Holder as an underwriter in any Registration Statement without the prior written consent of such Holder.

      

      

      	

            	3.	
              Registration Procedures.

            

      

      

      In connection with the Company’s registration obligations hereunder, the Company shall:

      

      

      (a) Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day
        prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all
        such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) use commercially reasonable efforts to cause its officers and
        directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the
        Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Required Holders (as defined below) shall reasonably object in good faith, provided that, the Company
        is notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related
        Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex C (a “Selling Stockholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day following the date on
        which such Holder receives draft materials in accordance with this Section. The Company shall not be required to include any Registrable Securities in the Registration Statement for any Holder that has not provided such Selling Stockholder
        Questionnaire.

      

      

      (b) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement
        and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such
        additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the
        terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment
        thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained
        therein that would constitute material non-public information regarding the Company or any of its subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the
        disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such
        Registration Statement as so amended or in such Prospectus as so supplemented.

       

      

      
        
          

      

      (c) If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of
        Common Stock then registered in a Registration Statement, then the Company shall, subject to Sections 2(b) and 2(c), if applicable, file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional
        Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.

      

      

      (d) Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof,
        be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if
        requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed,
        (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any
        post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional
        information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation
        of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or
        the initiation or threatening of any action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (a “Proceeding) for such purpose, (v) of the occurrence
        of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be
        incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it
        will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and
        (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow
        continued availability of a Registration Statement or Prospectus; provided, however, that in no event shall any such notice
        contain any information that would constitute material, non-public information regarding the Company or any of its subsidiaries.

      

      

      (e) Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order
        stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable
        moment.

      

      

      
        
          

      

      (f) If requested by a Holder, furnish to each Holder, without charge, at least one conformed copy of each such Registration
        Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by
        such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item that is available on the EDGAR system (or successor thereto) need not be
        furnished in physical form.

      

      

      (g) Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or
        supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section
        3(d).

      

      

      (h) Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or
        cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such
        jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably
        necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not
        then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.

      

      

      (i) If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates or
        book entry statements, as applicable, representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive
        legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may reasonably request; provided that Holder furnishes to Company a completed Holder Representation Letter in
        substantially the form attached hereto as Annex D and such other customary representations as may be required in connection therewith.

      

      

      (j) Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances
        taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a
        Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement
        nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
        misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend
        use of such Prospectus; provided that the Company shall only be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus for a period not to exceed 60 calendar days (which need
        not be consecutive days) in any 12-month period. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.

      

      

      
        
          

      

      (k) Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the
        Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act,
        promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with
        any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.

      

      

      (l) The Company shall use its commercially reasonable efforts to maintain eligibility for use of Form S-3 (or any successor form
        thereto) for the registration of the resale of the Registrable Securities once eligible to use such form.

      

      

      (m) The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of
        Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares.

      

      

      (n) The Company shall use its reasonable best efforts to cause (i) all Shares to be listed on each securities exchange or market,
        if any, on which the shares of Gem Common Stock have been listed.

      

      

      (o) The Company shall, at its sole expense, upon appropriate notice from a Holder stating that Registrable Securities have been
        sold or transferred pursuant to an effective Registration Statement, timely prepare and deliver certificates or evidence of book-entry positions representing the Registrable Securities to be delivered to a transferee pursuant to such Registration
        Statement, which certificates or book-entry positions shall be free of any restrictive legends and in such denominations and registered in such names as the undersigned may request. Further, the Company shall use its commercially reasonable
        efforts, at its sole expense, to cause its legal counsel to (a) issue to the transfer agent and maintain a “blanket” legal opinion instructing the transfer agent that, in connection with a sale or transfer of “restricted securities” (i.e.,
        securities issued pursuant to an exemption from the registration requirements of Section 5 of the Securities Act), the resale or transfer of which restricted securities has been registered pursuant to an effective Registration Statement by the
        holder thereof named in such Registration Statement, upon receipt of an appropriate broker representation letter and other such documentation as the Company’s counsel deems necessary and appropriate and after confirming compliance with relevant
        prospectus delivery requirements, is authorized to remove any applicable restrictive legend in connection with such sale or transfer and (b) if the Registrable Securities are not registered pursuant to an effective Registration Statement, issue to
        the transfer agent a legal opinion to facilitate the sale or transfer of the Registrable Securities and removal of any restrictive legends pursuant to any exemption from the registration requirements of Section 5 of the Securities Act that may be
        available to the undersigned, upon request; provided, that in the case of a request to remove such restrictive legends in connection with a sale or transfer of Registrable Securities pursuant to clause (a) or (b) above, the Company shall use its
        commercially reasonable efforts to cause the Company’s transfer agent to remove any such applicable restrictive legends in connection with such sale or transfer within two Business Days of such request. The Company shall be responsible for the fees
        of its transfer agent, its legal counsel and all DTC fees associated with any such request.

      

      

      
        
          

      

       4. Registration Expenses. All fees and expenses incident to the performance of or
        compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without
        limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to
        filings required to be made with any National Exchange on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without
        limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for
        Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, (vi) fees and expenses of all other
        Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement, and (vii) the reasonable fees and expenses, not to exceed $35,000, of one counsel for the selling Holders selected by the
        Holders of a majority of the Registrable Securities to be registered. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement
        (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable
        Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the extent provided for in the Purchase Agreement or
        this Agreement, any legal fees or other costs of the Holders.

      

      

      	

            	5.	
              Indemnification.

            

      

      

      (a) Indemnification by the Company. The Company shall,
        notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder and its affiliates, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as
        a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title
        or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and
        employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from
        and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable and documented attorneys’ fees) and expenses (collectively, “Losses”), as
        incurred, arising out of or based solely upon (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any
        preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of
        the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the
        performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such
        Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly
        for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified
        in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by
        such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the
        transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any
        Registrable Securities by any of the Holders in accordance with Section 6(f).

      

      

      
        
          

      

      (b) Indemnification by Holders. Each Holder shall, severally and not
        jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
        officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon any untrue or alleged untrue statement of a
        material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
        stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that such untrue
        statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus, including information provided in the Selling Stockholder
        Questionnaire or regarding the proposed method of distribution of Registrable Securities that was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has
        approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such
        Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable
        Securities included in the Registration Statement giving rise to such indemnification obligation.

      

      

      (c) Conduct of Indemnification Proceedings. If any Proceeding shall
        be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought
        (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the
        Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or
        liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have
        materially and adversely prejudiced the Indemnifying Party.

      

      

      An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense
        thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed
        promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such
        Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying
        Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense
        thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written
        consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party
        is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

      

      

      
        
          

      

      Subject to the terms of this Agreement, all reasonable and documented fees and expenses of the Indemnified Party (including
        reasonable and documented fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within
        ten Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such
        Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

      

      

      (d) Contribution. If the indemnification under Section 5(a) or 5(b)
        is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate
        to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
        Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material
        fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or
        omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection
        with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.

      

      

      The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
        pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable
        Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by
        reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

      

      

      The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying
        Parties may have to the Indemnified Parties.

      

      

      
        
          

      

      
        	 	
                6.

              	
                Miscellaneous.

              

      

      

      

      (a) Remedies. In the event of a breach by the Company or by a Holder
        of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be
        entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
        provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

      

      

      (b) No Piggyback on Registrations; Prohibition on Filing Other Registration
            Statements. Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The
        Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the
        Company from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements, nor preparing and filing with the Commission a
        registration statements on Form S-8 relating to its equity incentive plans.

      

      

      (c) Discontinued Disposition. By its acquisition of Registrable
        Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities
        under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be
        resumed. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.

      

      

      (d) Amendments and Waivers. The provisions of this Agreement,
        including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the
        Required Holders, provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall be required. If a
        Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced
        pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions
        hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable
        Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be
        amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this
        Agreement unless the same consideration also is offered to all of the parties to this Agreement.  As used herein, “Required Holders” means Holders of 50.1% or more of the then outstanding
        Registrable Securities (for purposes of clarification, this includes any securities issuable upon conversion or exercise of any Registrable Security).

      

      

      (e) Notices. Any and all notices or other communications or
        deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.

      

      

      
        
          

      

      (f) Successors and Assigns. This Agreement shall inure to the
        benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written
        consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 9.04 of the Purchase Agreement.

      

      

      (g) No Inconsistent Agreements. Neither the Company nor any of its
        subsidiaries has entered, as of the date hereof, nor shall the Company or any of its subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights
        granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Neither the Company nor any of its subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its
        securities to any Person that have not been satisfied in full.

      

      

      (h) Execution and Counterparts. This Agreement may be executed in
        two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both
        parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
        (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page was an original thereof.

      

      

      (i) Governing Law. All questions concerning the construction,
        validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement.

      

      

      (j) Cumulative Remedies. The remedies provided herein are cumulative
        and not exclusive of any other remedies provided by law.

      

      

      (k) Severability. If any term, provision, covenant or restriction of
        this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way
        be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
        covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
        invalid, illegal, void or unenforceable.

      

      

      (l) Headings. The headings in this Agreement are for convenience
        only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.

      

      

      (m) Independent Nature of Holders’ Obligations and Rights. The
        obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained
        herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of
        group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company
        acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including
        without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of
        the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly
        understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.

      

      

      ********************

       

      

      (Signature Pages Follow)

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

      

      

      	

            	
              DISC MEDICINE OPCO, INC.

            
	

            	

            	

            
	

            	
              By:

            	

            
	

            	
              Name:

            	

            
	

            	
              Title:

            	

            

      

      

      [SIGNATURE PAGE OF HOLDERS FOLLOWS]

      

      

      
        
          

      

      [SIGNATURE PAGE OF HOLDERS TO DISC RRA]

      

      

      	
              Name of Holder:

            	

            	

            
	

            	

            	

            

      	
              Signature of Authorized Signatory of Holder:

            	

            	

            
	

            	

            	

            

      	
              Name of Authorized Signatory:

            	

            	

            
	

            	

            	

            

      	
              Title of Authorized Signatory:

            	

            	

            

      

      

      [SIGNATURE PAGES CONTINUE]

       

      

      
        
          

      

      Annex A

      Plan of Distribution

      

      

      Each Selling Stockholder (the “Selling Stockholders”) of the securities and any of their
        pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or
        in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

      

      

      	

            	●	
              ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

            

      	

            	●	
              block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the
                transaction;

            

      	

            	●	
              purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

            

      	

            	●	
              an exchange distribution in accordance with the rules of the applicable exchange;

            

      	

            	●	
              privately negotiated transactions;

            

      	

            	●	
              settlement of short sales;

            

      	

            	●	
              in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;

            

      	

            	●	
              through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

            

      	

            	●	
              a combination of any such methods of sale; or

            

      	

            	●	
              any other method permitted pursuant to applicable law.

            

      

      

      The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as
        amended (the “Securities Act”), if available, rather than under this prospectus.

      

      

      Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
        commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the
        case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

      

      

      In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
        or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their
        short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one
        or more derivative securities that require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this
        prospectus (as supplemented or amended to reflect such transaction).

      

      

      The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the
        meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or
        discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

      

      

      
        
          

      

      The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has
        agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

      

      

      We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
        without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, and without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act
        or any other rule of similar effect, or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or
        licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or
        an exemption from the registration or qualification requirement is available and is complied with.

      

      

      Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
        simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be
        subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will
        make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the
        Securities Act).

      

      

      
        
          

      

      Annex B

      SELLING STOCKHOLDERS

      

      

      For additional information regarding the issuances of those shares of common stock being registered for resale in this registration statement, see
        “Private Placement of Shares of Common Stock” and “Business Combination of [•] and [•]” above. We are registering the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time.

      

      

      The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the
        selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of the shares of common stock, as of ________, 2022.

      

      

      The third column lists the shares of common stock being offered by this prospectus by the selling stockholders.

      

      

      The fourth column reflects the number of shares of common stock beneficially owned by each selling stockholder, assuming the sale of all of the
        shares offered by the selling stockholders pursuant to this prospectus.

      

      

       The selling stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

       

      

      	
              Name of Selling Stockholder

            	 	
              Number of shares 

              of Common Stock 

              Owned Prior to 

              Offering

            	 	
              Maximum Number 

              of shares of 

              Common Stock to 

              be Sold Pursuant to 

              this Prospectus

            	 	
              Number of shares 

              of Common Stock 

              Owned After 

              Offering

            

      

      

      
        
          

      

      Annex C

      Selling Stockholder Notice and Questionnaire

      

      

      The undersigned owner of  Registrable Securities (as such term is defined in the Registration Rights Agreement) of Disc Medicine, Inc., a Delaware
        corporation (the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”)

        a Registration Statement for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with
        the terms of the Registration Rights Agreement dated as of December 28, 2022 to which the Company and the undersigned are parties (the “Registration Rights Agreement”). A copy of the
        Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

      

      

      Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
        holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related
        prospectus.

      

      

      NOTICE

      

      

      The undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities
        hereby elects to include the Registrable Securities owned by it in the Registration Statement.

       

      

      
        

       

      

      The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

      

      

      QUESTIONNAIRE

      

      

      	
              1.

            	
              Name.

            
	

            	
              (a)

            	
              Full Legal Name of Selling Stockholder

            
	

            	

            	

            
	

            	
              (b)

            	
              Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:

            
	

            	

            	

            
	 	
              (c)

            	
              Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the
                securities covered by this Questionnaire):

            
	

            	

            	

            

      

      

      2. Address for Notices to Selling Stockholder:

       

      

      	
              Telephone:

            	

            
	

            	

            

      	
              Fax:

            	

            

       

      

      
        
          

      

      	
              Contact Person:

            	 

      

      

      3. Broker-Dealer Status:

      

      

      	

            	
              (a)

            	
              Are you a broker-dealer?

            
	Yes ☐ No ☐
	

            	

            	

            
	

            	
              (b)

            	
              If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?

            
	

            	

            	

            
	Yes ☐ No ☐
	 	 	 
	

            	
              Note:

            	
              If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

            
	 	 	 
	

            	
              (c)

            	
              Are you an affiliate of a broker-dealer?

            
	

            	

            	

            
	
              Yes ☐ No ☐

            
	 	 	 
	

            	
              (d)

            	
              If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the
                time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

            
	

            	

            	

            
	
              Yes ☐ No ☐

            
	 
	

            	
              Note:

            	
              If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

            

      

      

      4. Ownership of Securities of the Company Owned by the Selling Stockholder.

      

      

      Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the
        Company other than the securities issuable pursuant to the Purchase Agreement.

      

      

      	

            	
              (a)

            	
              Type and Amount of other Company securities owned by the Selling Stockholder (including beneficially owned, as applicable):

            
	

            	

            	 
	

            	

            	 

      

      

      5. Relationships with the Company:

      

      

      Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders
        (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.

       

      

      
        State any exceptions here:

        

        

        	 	 
	 	 

         

        

      

      
        
          

      

      The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur
        subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or
        its affiliates.

      

      

      By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the
        inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the
        preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

      

      

      IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
        or by its duly authorized agent.

      

      

      	
              Date:

            	 	 	
              Beneficial 

              Owner:

            	 
	

            	 	 	

            	

            

      	

            	
              By:

            	

            
	

            	
              Name:

            	

            
	

            	
              Title:

            	 

      

      

      PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:

      

      

      
        
          

      

      Annex D

      HOLDER REPRESENTATION LETTER

      

      

      ________ __, 20__

       

      Disc Medicine, Inc.

      

      

      Goodwin Procter LLP

      100 Northern Ave.

      Boston, MA 02110

      

      

      To Whom It May Concern:

      

      

      The undersigned (the “Holder”) hereby requests that the federal securities law
        restrictive legend be removed from the book entries representing _________ of shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”),
          of Disc Medicine, Inc. (the “Company”). In connection with the legend removal, Holder hereby represents to, and agrees with, you as follows:

      

      

      	 	1.	
              The Shares are owned of record and beneficially by Holder.

            

      

      

      	

            	2.	
              Holder agrees that, if the Shares are not eligible to be sold pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities

                    Act”), any offer, sale or transfer of, or other transaction involving, the Shares will only be made (i) pursuant to the Company’s Registration Statement (the “Registration
                    Statement”) filed pursuant to the Securities Act, in a transaction contemplated in the “Plan of Distribution” section of the prospectus included in the Registration Statement and in accordance with the terms and conditions
                set forth in the Registration Rights Agreement, dated December 28, 2022, by and among Disc Medicine, Inc. and Purchasers (the “RRA”), including, but not limited to, the
                restrictions upon sales that may be imposed as set forth in the RRA or (ii) to an exemption from the registration requirements of the Securities Act subject to receipt of a legal opinion from Goodwin Procter LLP or other counsel acceptable
                to the Company that such offer, sale or transfer is exempt from the registration requirements of the Securities Act;

            

      

      

      	

            	3.	
              Holder agrees, for the benefit of the Company and Goodwin Procter LLP, that it will (i) not offer and sell, or cause or permit to be offered or sold, any Shares in violation of federal and state
                securities laws, including, without limitation, prospectus delivery requirements of the Securities Act and (ii) immediately stop selling or transferring Shares pursuant to the Registration Statement upon receipt of written notice from the
                Company that the Registration Statement may not be used to effect offers, sales or other transfers of the Shares;

            

      

      

      	

            	4.	
              Holder (or, in the case of individuals, Holder’s employer) has in place internal policies and procedures to monitor and ensure that no offer, sale or transfer of, or other transaction involving,
                the Shares is made in violation of the foregoing restrictions, and Holder will monitor all transactions involving the Shares for the purpose of ensuring that they comply with all federal and state securities laws;

            

      

      

      
        
          

      

      	

            	5.	
              Holder agrees that, in the event the Company in the future reasonably determines that the Shares should be evidenced by a certificate bearing appropriate restrictive transfer legends (and/or a
                book-entry including a notation of restricted security status) because the Registration Statement is not available for the resale of the Shares and the Shares are not eligible to be sold pursuant to Rule 144 promulgated under the Securities
                Act, the undersigned will take all reasonable action to cause all Shares it then owns or controls to be delivered promptly to the Company’s transfer agent in exchange for one or more stock certificates or warrant certificates bearing
                restrictive legends (and/or book-entries including a notation of restricted security status) deemed appropriate by the Company;

            

      

      

      	

            	6.	
              Holder acknowledges that the Shares shall remain “restricted securities” as that term is defined for purposes of the Securities Act notwithstanding the removal of their federal securities law
                restrictive legend, and Holder agrees that it will inform its brokers of the fact that such securities are “restricted securities” before any offer, sale or transfer of, or other transaction involving, the Shares.  In addition, Holder shall
                notify the Company of all brokers in whose name, or on whose behalf, any of the Shares are being held on behalf of Holder; and

            

      

      

      	

            	7.	
              Holder is familiar with the requirements for effecting resales or transfers of, or other transactions involving, the Shares in compliance with federal and state securities laws and acknowledges and
                agrees that the Company and Goodwin Procter LLP (together, the “Indemnified Parties”) are relying on Holder’s representations and agreements in this letter. Holder will indemnify
                and hold harmless the Indemnified Parties against any and all loss, damage, claim, liability and expense arising out of or resulting from the breach of any such representation or agreement.

            

      

      

      	

            	
              Very truly yours,

            
	

            	

            
	

            	
              [HOLDER]

            
	

            	

            
	

            	
              By:

            	

            	

            
	

            	
              Name:

            
	

            	
              Title:Exhibit 10.2

        

       

        

      CONTINGENT VALUE RIGHTS AGREEMENT

       

      BETWEEN

       

      GEMINI THERAPEUTICS, INC.

       

      and

       

      CONTINENTAL STOCK TRANSFER AND TRUST COMPANY

       

      Dated as of December 29, 2022

       

      
        
          

      

      CONTINGENT VALUE RIGHTS AGREEMENT

       

      THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of December 29, 2022 is entered into by and among Gemini Therapeutics, Inc. a Delaware corporation (“Gem”),
          and Continental Stock Transfer and Trust Company, as initial Rights Agent (as defined herein).

       

      PREAMBLE

       

      WHEREAS, Gem, Gemstone Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Gem (“Merger
            Sub”), and Disc Medicine, Inc., a Delaware corporation (the “Company”), have entered into an Agreement and Plan of Merger and Reorganization, dated as of August 9, 2022 (the
        “Merger Agreement”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company
        surviving the Merger as a wholly-owned subsidiary of Gem (the “Surviving Corporation”);

       

      WHEREAS, pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, Gem has agreed to provide to the Holders (as
        defined herein), who shall initially be Persons who are stockholders of Gem as of immediately prior to the Effective Time, contingent value rights as hereinafter described, by way of a dividend or distribution consistent with the Merger Agreement;
        and

       

      WHEREAS, the parties have done all things necessary to make the contingent value rights, when issued pursuant to the Merger Agreement and hereunder,
        the valid obligations of Gem and to make this Agreement a valid and binding agreement of Gem, in accordance with its terms.

       

      NOW, THEREFORE, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for
        the proportionate benefit of all Holders, as follows:

       

      ARTICLE 1

      DEFINITIONS

       

      Section 1.1          Definitions.

       

      Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement. The following terms have the
        meanings ascribed to them as follows:

       

      “Acting Holders” means, at the time of determination, Holders of at least 25% of the
        outstanding CVRs as set forth on the CVR Register.

       

      “Assignee” has the meaning set forth in Section
            7.5

       

      
        
          

      

      “Calendar Quarter” means the successive periods of three (3) consecutive calendar months
        ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect; provided, however that (a) the first Calendar Quarter shall commence on the date of this Agreement and shall end on the first December 31
        thereafter, and (b) the last Calendar Quarter shall commence on the first day after the full Calendar Quarter immediately preceding the effective date of the termination or expiration of this Agreement and shall end on the effective date of the
        termination or expiration of this Agreement.

       

      “CVR” means a contingent contractual right of Holders to receive CVR Payments pursuant to
        the Merger Agreement and this Agreement.

       

      “CVR Payment” means a number of shares of Gem Common Stock equal to (i) the CVR Proceeds
        for an applicable Calendar Quarter, divided by (ii) the volume weighted average of their closing market prices for the five (5) trading days ending the day prior to the date of issuance pursuant to this Agreement.

       

      “CVR Period” means the period beginning immediately following the Effective Time and ending
        on the tenth anniversary of the Closing Date.

       

      “CVR Proceeds” means the amount of Gross Proceeds received by Gem during an applicable
        Calendar Quarter, less the applicable accrued and reasonably documented Permitted Deductions, in each case as calculated in accordance with GAAP using the policies, methodologies, processes and procedures used to prepare Gem’s most recent year-end
        financial statements prior to the commencement of such Calendar Quarter.

       

      “CVR Register” has the meaning set forth in Section
            2.3(b).

       

      “Disposition” means the sale, license, transfer, disposition or other monetizing event of
        any Potentially Transferable Asset (including any such sale or disposition or monetizing event of equity securities in any Subsidiary established by Gem during the Disposition Period to hold any right, title or interest in or to any Potentially
        Transferable Asset), in each case during the Disposition Period.

       

      “Disposition Period” means the period beginning on the execution date of the Merger
        Agreement and ending on the date that is twelve-months after the Closing Date.

       

      “Gross Proceeds” means, without duplication, any and all consideration of any kind that is
        paid to Gem, or is received by, Gem or any of its Affiliates during the CVR Period in respect of a Disposition. The value of any securities (whether debt or equity) or other non-cash property constituting Gross Proceeds shall be determined as
        follows: (A) the value of securities for which there is an established public market shall be equal to the volume weighted average of their closing market prices for the five (5) trading days ending the day prior to the date of payment to, or
        receipt by, Gem or its relevant Affiliate, and (B) the value of securities that have no established public market and the value of consideration that consists of other non-cash property, shall be the fair market value thereof as of the date of
        payment to, or receipt by, Gem or its relevant Affiliate.

       

      
        
          

      

      “Holder” means, at the relevant time, a Person in whose name CVRs are registered in the CVR
        Register.

       

      “Loss” has the meaning set forth in Section
            3.2(g).

       

      “Majority of Holders” means, at any time, the registered Holder or Holders of more than 50%
        of the total number of CVRs registered at such time, as set forth on the CVR Register.

       

      “Notice” has the meaning set forth in Section
            7.1.

       

      “Officer’s Certificate” means a certificate signed by the chief executive officer and the
        chief financial officer of Gem, in their respective official capacities.

       

      “Permitted Deductions” means the following costs or expenses, without duplication:

       

      (a)          any applicable Tax (including any
            unreimbursed applicable value added or sales taxes) imposed on Gross Proceeds and payable by Gem, the Company or any of their respective Affiliates (regardless of whether the due date for such Taxes arises during or after the Disposition
            Period) to any tax authority and, without duplication, any income or other similar Taxes payable by Gem, the Company or any of their respective Affiliates that would not have been incurred by Gem, the Company or any of their respective
            Affiliates but for the Gross Proceeds; provided that, for purposes of calculating income Taxes incurred by Gem, the Company or any of their respective Affiliates in respect of the Gross Proceeds, any such income Taxes shall be computed after
            taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits) of Gem, the Company or any of their respective Affiliates as of the Closing Date that are available to offset such gain after taking into
            account any limits of the usability of such attributes, including under Section 382 of the Code (as defined herein) as reasonably determined by a nationally recognized tax advisor (and for the sake of clarity such income taxes shall be
            calculated without taking into account any net operating losses or other Tax attributes generated by Gem, the Company or any of their respective Affiliates after the Closing Date);

       

      (b)          any reasonable and documented
            out-of-pocket expenses incurred by Gem or any of its Affiliates in respect of its performance of this Agreement following the Closing Date or in respect of its performance of any agreement in connection with any Potentially Transferable Asset,
            including any costs related to the prosecution, maintenance or enforcement by Gem or any of its Subsidiaries of the intellectual property rights of any such Potentially Transferable Asset (but excluding any costs related to a breach of this
            Agreement, including costs incurred in litigation in respect of the same);

       

      (c)          any reasonable and documented
            out-of-pocket expenses incurred or accrued by Gem or any of its Affiliates in connection with the negotiation, entry into and closing of any Disposition of any Potentially Transferable Asset, including any brokerage fee, finder’s fee, opinion
            fee, success fee, transaction fee, service fee or other fee, commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party acting on behalf of Gem or its Affiliates in relation
            thereto;

       

      
        
          

      

      (d)          any Losses incurred and paid by Gem or
            any of its Affiliates arising out of any third party claims, demands, actions or other proceedings relating to or in connection with any Disposition, including Losses actually incurred or paid (or reasonably expected to be actually incurred or
            paid) in connection with indemnification obligations of Gem or any of its Affiliates set forth in any Sale Agreement;

       

      (e)          any Liabilities borne by Gem or any of
            its Affiliates pursuant to Contracts related to Potentially Transferable Assets, including costs arising from the termination thereof (in each case only to the extent not included in the calculation of Gem Net Cash (as defined in the Merger
            Agreement); and

       

      (f)          any Liabilities which Gem reasonably and
            in good faith determines (with the approval of the Special Committee) should have been, but were not, deducted from “Gem Net Cash” (as defined in the Merger Agreement) pursuant to clause (B) of such definition, in connection with the Closing of
            the Merger, to the extent that deduction of such Liabilities would have resulted in a change in the Exchange Ratio under the Merger Agreement were such amounts properly deducted (including after giving effect to the Higher Gem Net Cash Amount
            and the Lower Gem Net Cash Amount);

       

      provided that (a) no Permitted Deductions shall be deducted until the aggregate amount of Permitted Deductions exceeds the CVR Expenditure Amount and (b) no Permitted
        Deductions shall be deducted if they are otherwise deducted from the calculation of Gem Net Cash (as defined in the Merger Agreement).

       

      “Permitted Transfer” means a Transfer of one or more CVRs (i) upon death of a Holder by
        will or intestacy; (ii) by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii) made
        pursuant to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (iv) if the Holder is a partnership or limited liability company, a distribution by the transferring partnership or
        limited liability company to its partners or members, as applicable (v) made by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation,
        limited liability company, partnership or other entity; (vi) in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary) or from such nominee to another nominee for the same
        beneficial owner, in each case as permitted by The Depository Trust Company (“DTC”); (vii) to Gem or its Affiliates; or (viii) as provided in Section
            2.6.

       

      “Person” shall mean any individual, partnership, joint venture, limited liability company,
        firm, corporation, unincorporated association or organization, trust or other entity, and shall include any successor (by merger or otherwise) of any such Person.

       

      “Potentially Transferrable Asset” means any and all assets, tangible and intangible,
        including, without limitation, patents, patent applications, know-how, trade secrets and other intellectual property rights, data, documentation, agreements and licenses, inventory related to drug products and raw materials, and biological
        materials, which Gem or any of its Subsidiaries owned or had rights to, as of immediately prior to the Effective Time.

       

      
        
          

      

      “Rights Agent” means the Rights Agent named in the first paragraph of this Agreement, until
        a successor Rights Agent shall have been appointed pursuant to Article 3 of this Agreement, and thereafter “Rights Agent” will mean such successor Rights Agent.

       

      “Sale Agreement” has the meaning set forth in Section 4.2.

       

      “Special Committee” has the meaning set forth in Section 4.2.

       

      “Transfer” means transfer, pledge, hypothecation, encumbrance, assignment or other
        disposition (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition, and each Contract, arrangement or understanding, whether or not in writing,
        to effect any of the foregoing.

       

      ARTICLE 2

      CONTINGENT VALUE RIGHTS

       

      Section 2.1          Holders of CVRs; Appointment of Rights Agent.

       

      (a)          The CVRs shall be issued and distributed
            by Gem in the form of a dividend, in connection with the Merger, to the Persons who as of immediately prior to the Effective Time are stockholders of record of Gem or have the right to receive Gem Common Stock as of immediately prior to the
            Effective Time, as contemplated by the Merger Agreement.

       

      (b)          Gem hereby appoints the Rights Agent to
            act as rights agent for Gem in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment.

       

      Section 2.2          Non-transferable.

       

      A Holder may not at any time Transfer CVRs, other than pursuant to a Permitted Transfer. Any attempted Transfer that is not a Permitted Transfer, in
        whole or in part, will be void ab initio and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange.

       

      Section 2.3          No Certificate; Registration; Registration of Transfer; Change of Address.

       

      (a)          Holders’ rights and obligations in
            respect of CVRs derive solely from this Agreement; CVRs will not be evidenced by a certificate or other instrument.

       

      
        
          

      

      (b)          The Rights Agent will maintain an
            up-to-date register (the “CVR Register”) for the purposes of (i) identifying the Holders of CVRs, (ii) determining Holders’ entitlement to CVRs and (iii) registering the CVRs and
            Permitted Transfers thereof. The CVR Register will initially show one position for the Rights Agent representing all of the CVRs provided to the holders of shares of Gem Common Stock held immediately prior to Closing. Gem and the Rights Agent
            may require evidence of payment of a sum sufficient to cover any stamp, documentary, registration, or other tax or governmental charge that is imposed in connection with (and would not have been imposed in connection with (and would have been
            imposed but for)) any such registration of transfer (or evidence that such taxes and charges are not applicable).

       

      (c)          Subject to the restriction on
            transferability set forth in Section 2.2, every request made to Transfer CVRs must be in writing and accompanied by a written instrument of Transfer reasonably acceptable to the
            Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association (a “signature guarantee”) and other requested documentation
            in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, by the Holder or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting
            forth in reasonable detail the circumstances relating to the Transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures, that the Transfer
            instrument is in proper form and the Transfer, is a Permitted Transfer and otherwise complies on its face with the other terms and conditions of this Agreement, register the Transfer of the applicable CVRs in the CVR Register. All Transfers of
            CVRs registered in the CVR Register will be the valid obligations of Gem, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor. No transfer of CVRs shall
            be valid until registered in the CVR Register and any transfer not duly registered in the CVR Register shall be void. Gem shall not be responsible for any costs and expenses related to any transfer or assignment of the CVRs (including the cost
            of any transfer tax).

       

      (d)          A Holder may make a written request to
            the Rights Agent to change such Holder’s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the
            CVR Register.

       

      Section 2.4          Payment Procedures.

       

      (a)          No later than forty-five (45) days
            following the end of each Calendar Quarter following the Closing, Gem shall (i) deliver to the Rights Agent, a certificate (each, a “CVR Certificate”) certifying to and specifying in
            reasonable detail, for such Calendar Quarter, the aggregate amount of (A) the CVR Proceeds received by Gem or its Affiliates during such fiscal quarter (or, in the case of the first delivery of a CVR Certificate hereunder, all CVR Proceeds
            received through the end of such Calendar Quarter); (B) the Permitted Deductions reflected in such CVR Proceeds; and (C) the CVR Payment payable to Holders, if any, in respect of such CVR Proceeds and (ii) deliver to the Rights Agent, or as the
            Rights Agent directs, the aggregate CVR Payment (if any). With respect to each Holder, the Rights Agent shall deliver, or cause to be delivered, a number of shares equal to the product determined by multiplying (i) the quotient determined by
            dividing (A) the number of shares representing the aggregate CVR Payment by (B) the total number of CVRs registered in the CVR Register at such time, by (ii) the number of CVRs registered to such Holder in the CVR Register at such time. For the
            avoidance of doubt Gem shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this Section 2.4(a) and the
            satisfaction of each of Gem’s obligations set forth in this Section 2.4(a).

       

      
        
          

      

      (b)          The parties hereto agree to treat the
            distribution of the CVRs as constituting a nontaxable stock distribution under Section 305 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”)
            and the receipt of CVR Payments as a nontaxable exercise of the right to receive stock under the CVRs. The parties hereto will not take any position to the contrary on any Tax Return or for other Tax purposes except as required by a change in
            or clarification to applicable Law after the date hereof.

       

      (c)          Gem and the Rights Agent will be
            entitled to deduct and withhold, or cause to be deducted and withheld, from any CVR Payment otherwise payable pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any
            provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld, such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid to the Holder in respect of which
            such deduction and withholding was made. The Rights Agent shall request from each Holder an IRS Form W-9 or applicable IRS Form W-8 at such time or times as is necessary to permit any payment under this Agreement to be made without U.S. federal
            backup withholding. Prior to making any such Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any Holder, the Rights Agent will, to the extent reasonably practicable, provide notice to
            the Holder of such potential Tax deduction or withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms in order to avoid or reduce such withholding amounts; provided that the time period for payment of a CVR Payment by the Rights Agent set forth in Section 2.4(a) will be extended by a period equal to
            any delay caused by the Holder providing such forms, provided, further, that in no
            event shall such period be extended for more than ten (10) Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent.

       

      (d)          Any portion of a CVR Payment that
            remains undistributed to the Holders six (6) months after the end of the applicable Calendar Quarter (including by means of invalid addresses on the CVR Register) will be delivered by the Rights Agent to Gem or a person nominated in writing by
            Gem (with written notice thereof from Gem to the Rights Agent), and any Holder will thereafter look only to Gem for payment of such CVR Payment (which shall be without interest).

       

      Section 2.5          No Voting, Dividends or Interest.

       

      (a)          CVRs will not have any voting or
            dividend rights, and interest will not accrue on any amounts payable in respect of CVRs.

       

      (b)          CVRs will not represent any equity or
            ownership interests in Gem or any of its Subsidiaries or in the Surviving Corporation. The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. It is hereby
            acknowledged and agreed that a CVR shall not constitute a security of Gem or any of its Subsidiaries or of the Surviving Corporation.

       

      
        
          

      

      (c)          By voting in favor of the adoption of
            the Merger Agreement, the approval of the principal terms of the Merger, and the consummation of the Merger or participating in the Merger and receiving the benefits thereof, including the right to receive CVRs and any consideration payable in
            connection with the CVRs, each Holder hereby acknowledges and agrees that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Gem’s control, and there is
            no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly possible that no Disposition will occur prior to the expiration of the Disposition Period and
            that there will not be any Gross Proceeds that may be the subject of a CVR Payment. It is further acknowledged and agreed that neither Gem nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any
            implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this Section 2.5(b) is an essential and material term of this Agreement.

       

      Section 2.6          Ability to Abandon CVR.

       

      A Holder may at any time, at such Holder’s option, abandon all of such Holder’s remaining rights represented by CVRs by transferring such CVR to Gem or
        a person nominated in writing by Gem (with written notice thereof from Gem to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Gem of
        such transfer and cancellation. Nothing in this Agreement is intended to prohibit Gem or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion.

       

      ARTICLE 3

      THE RIGHTS AGENT

       

      Section 3.1          Certain Duties and Responsibilities.

       

      (a)          The Rights Agent will not have any
            liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (in each case as determined by a
            final non-appealable judgment of court of competent jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by Gem to
            the Rights Agent during the twelve (12) months immediately preceding the event for which recovery from the Rights Agent is being sought. Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special,
            punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the
            form of action.

       

      
        
          

      

      (b)          The Rights Agent shall not have any duty
            or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to
            initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Gem or the Company. The Rights Agent may (but shall not be required to) enforce all rights of action under this Agreement and any related claim,
            action, suit, audit, investigation or proceeding instituted by the Rights Agent may be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their
            respective rights or interests may appear on the CVR Register.

       

      Section 3.2          Certain Rights of Rights Agent.

       

      (a)          The Rights Agent undertakes to perform
            such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent.

       

      (b)          The Rights Agent may rely and will be
            protected by Gem in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith to
            be genuine and to have been signed or presented by or on behalf of Gem.

       

      (c)          Whenever the Rights Agent deems it
            desirable that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may (i) rely upon an Officer’s Certificate and (ii) incur no liability and be held harmless by Gem for or in respect of any
            action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer’s Certificate.

       

      (d)          The Rights Agent may engage and consult
            with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, gross negligence or willful misconduct (in each case, as determined by a final, non-appealable judgment of a court of competent
            jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon.

       

      (e)          Any permissive rights of the Rights
            Agent hereunder will not be construed as a duty.

       

      (f)          The Rights Agent will not be required to
            give any note or surety in respect of the execution of its powers or otherwise under this Agreement.

       

      (g)          Gem agrees to indemnify the Rights Agent
            for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, cost or expense (each, a “Loss”) suffered or incurred by the Rights
            Agent and arising out of or in connection with the Rights Agent’s performance of its obligations under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges,
            demands, actions or suits arising out of or in connection in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim
            of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the
            Rights Agent’s gross negligence, bad faith or willful misconduct.

       

          

      
        
          

      

      (h)          In addition to the indemnification
            provided under Section 3.2(g), Gem agrees (i) to pay the fees of the Rights Agent in connection with the Rights Agent’s performance of its obligations hereunder, as agreed upon in
            writing by the Rights Agent and Gem on or prior to the date of this Agreement, and (ii) to reimburse the Rights Agent for all reasonable and documented out-of-pocket expenses and other disbursements incurred in the preparation, delivery,
            negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including all Taxes (other than income, receipt, franchise or similar Taxes) and governmental charges, incurred by
            the Rights Agent in the performance of its obligations under this Agreement, except that Gem will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent for the fees of counsel in connection with any lawsuit
            initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of Section 2.4(a), Section 2.4(b) or Section 3.2(g), if Gem is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such
            suit.

       

      (i)          No provision of this Agreement shall
            require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds
            or adequate indemnification against such risk or liability is not reasonably assured to it.

       

      (j)          The Rights Agent will not be deemed to
            have knowledge of any event of which it was supposed to receive notice hereunder but has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each
            case, unless and until it has received such notice in writing.

       

      (k)          The Rights Agent may execute and
            exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct
            of any such attorney or agents or for any loss to Gem or the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of
            a court of competent jurisdiction) in the selection and continued employment thereof.

       

      (l)          Gem shall perform, acknowledge and
            deliver or cause to be performed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the
            provisions of this Agreement.

       

      
        
          

      

      (m)          The Rights Agent shall not be liable for
            or by reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Gem
            only.

       

      (n)          The Rights Agent shall act hereunder
            solely as agent for Gem and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written
            demand from any Holders with respect to any action or default by Gem, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any
            demand upon Gem.

       

      (o)          The Rights Agent may rely on and be
            fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an “eligible guarantor institution” that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable
            “signature guarantee program” or insurance program in addition to, or in substitution for, the foregoing; or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been
            altered, changed, amended or repealed.

       

      (p)          The Rights Agent shall not be liable or
            responsible for any failure of Gem to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable
            regulation or law.

       

      (q)          The obligations of Gem and the rights of
            the Rights Agent under this Section 3.2, Section 3.1 and Section 2.4
            shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent.

       

      Section 3.3          Resignation and Removal; Appointment of Successor.

       

      (a)          The Rights Agent may resign at any time
            by written notice to Gem. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30) days following the date that such resignation notice is delivered), and such
            resignation will be effective on the earlier of (x) the date so specified and (y) the appointment of a successor Rights Agent.

       

      (b)          Gem will have the right to remove the
            Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty (30) days prior to the date so specified (or, if earlier, the appointment of
            the successor Rights Agent).

       

      (c)          If the Rights Agent resigns, is removed
            or becomes incapable of acting, Gem will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if Gem fails to make such appointment within a period of thirty (30) days after giving notice of such removal or after
            it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The
            successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this Section 3.3(c) and Section
                3.4, become the Rights Agent for all purposes hereunder.

       

      
        
          

      

      (d)          Gem will give notice to the Holders of
            each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with Section 7.2. Each notice will include the name and address of the
            successor Rights Agent. If Gem fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Gem.

       

      (e)          Notwithstanding anything to the contrary
            in this Section 3.3, unless consented to in writing by the Acting Holders, Gem will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national
            reputation or the corporate trust department of a commercial bank.

       

      (f)          The Rights Agent will reasonably
            cooperate with Gem and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register,
            to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing.

       

      Section 3.4          Acceptance of Appointment by Successor.

       

      Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Gem and to the resigning
        or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of
        the Rights Agent; provided that upon the request of Gem or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument
        transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent.

       

      ARTICLE 4

      COVENANTS

       

      Section 4.1          List of Holders.

       

      Gem will furnish or cause to be furnished to the Rights Agent, in such form as Gem receives from Gem’s transfer agent (or other agent performing
        similar services for Gem), the names and addresses of the Holders within fifteen (15) Business Days following the Closing Date.

       

      Section 4.2          CVR Committee; Efforts.

       

      
        
          

      

      (a)          The Gem Board has delegated, to a
            special committee of the Gem Board comprised exclusively of Georges Gemayel (the “Special Committee”) the sole responsibility, authority and discretion during the Disposition Period
            with respect to (i) managing the Potentially Transferable Assets, and (ii) conducting any sale or transfer process (including engagement of advisors) with respect to a Disposition during the Disposition Period. The Special Committee shall also
            be empowered with the authority to authorize and direct any officer of Gem to negotiate, execute and deliver a definitive written agreement with respect to a Disposition (a “Sale Agreement”)
            in the name and on behalf of Gem, as well as to identify and retain advisers and consultants.

       

      (b)          The delegation of responsibility and
            authority to the Special Committee set forth in Section 4.2(a) shall not be revoked or modified at any time during the Disposition Period. The Special Committee and the Gem Board shall not have any liability to the Holders for any actions taken
            or not taken in connection with the matters set forth herein. No provision of this Agreement shall require the Special Committee or any members thereof to expend or risk its, his or her own funds or otherwise incur any financial liability in
            the performance of any duties hereunder or in the exercise of any rights or powers.

       

      (c)          The Holders shall be intended
            third-party beneficiaries of the provisions of this Agreement and shall be entitled to specifically enforce the terms hereof; provided, that under no circumstances shall the rights of Holders as third-party beneficiaries pursuant to this Section 4 be enforceable by such Holders or any other Person acting for or on their behalf other than the Special Committee. The Special Committee has the sole power and authority to act
            on behalf of the Holders in enforcing any of their rights hereunder.

       

      (d)          During the Disposition Period, Gem will,
            and will cause its Subsidiaries to, use commercially reasonable efforts (i) to utilize the CVR Expenditure Amount to maintain the Potentially Transferable Assets unless otherwise approved by the Special Committee, and (ii) effectuate a
            Disposition of the Potentially Transferable Assets, at the direction of the Special Committee, including the negotiation and execution of a Sale Agreement and completion of the transactions contemplated thereby.  Further, Gem will not take any
            actions for the primary purpose of frustrating the payment of CVR Proceeds.

       

      (e)          Subject to the foregoing clause (d), (i)
            the Holders acknowledge that Gem has a fiduciary obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay CVR Proceeds will not create any express or implied obligation to operate its
            business in any particular manner in order to maximize such CVR Proceeds, (ii) except as expressly set forth in this Agreement, the Holders are not relying on any representation of Gem or any other Person with regard to any Disposition or other
            action involving the Potentially Transferrable Assets following the Closing, and neither Gem nor any other Person has provided, or can provide, any assurance to the Holders that any CVR Proceeds will in fact be earned and paid, and (iii) none
            of Gem or any of its Subsidiaries, officers or directors shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to the sale of Potentially Transferable
            Assets. Gem and its Affiliates will not be required to expend any out-of-pocket amounts in excess of the CVR Expenditure Amount during the Disposition Period, but, for clarity, any amounts which are or will become payable upon consummation of
            the Disposition and/or the payment of CVR Proceeds and which constitute Permitted Deductions shall be disregarded for purposes of the first clause of this sentence.

       

      
        
          

      

      (f)          Following the Disposition Period, Gem
            shall be permitted to take any action in respect of the Potentially Transferable Assets in order to satisfy any wind-down and termination Liabilities of the Potentially Transferable Assets.

       

      Section 4.3          Prohibited Actions.  Unless approved by written consent or resolution by the Special Committee, prior to the end of the Disposition Period, (a) Gem shall not grant any lien, security interest, pledge or
            similar interest in, or otherwise sell or Transfer, any Potentially Transferable Assets or any CVR Proceeds, and (b) Gem shall not, and shall not permit its Affiliates to, grant, assign, transfer or otherwise convey any Potentially Transferable
            Assets (including any option to obtain rights) to any third party.

       

      Section 4.4          Books and Records.Until the end of the CVR Period, Gem shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to support the
            applicable CVR Payments payable hereunder in accordance with the terms specified in this Agreement.

       

      Section 4.5          Audits. Gem agrees to maintain, for at least two years after the last possible CVR Payment, all books and records relevant to the calculation of the Permitted Deductions.
            Subject to reasonable advance written notice from the Acting Holders and prior execution and delivery by it and an independent accounting firm of national reputation chosen by the Acting Holders (the “Accountant”) of a reasonable and customary confidentiality/nonuse agreement, which confidentiality/nonuse agreement shall not prohibit the Acting Holders from communicating any such information with the Holders who have
            a need to know such information, provided that any such recipients are subject to confidentiality obligations with respect thereto, Gem shall permit the Acting Holders and the Accountant, acting as agent of the Acting Holders, to have access
            during normal business hours to the books and records of Gem as may be reasonably necessary to audit the calculation of the CVR Payment and the Permitted Deductions. Notwithstanding anything in this Agreement to the contrary, in no event shall
            Gem be required to provide any tax returns or any other tax information it deems confidential to the Acting Holders or any other party pursuant to this Agreement.

       

      ARTICLE 5

      AMENDMENTS

       

      Section 5.1          Amendments Without Consent of Holders or Rights Agent.

       

      (a)          Gem, at any time and from time to time,
            may (without the consent of any Person, other than the Rights Agent, with such consent not to be unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement for any of the following purposes, without the
            consent of any of the Holders,

       

      
        
          

      

      (i)          to evidence the appointment of another
            Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof;

       

      (ii)         subject to Section 6.1, to evidence
            the succession of another person to Gem and the assumption of any such successor of the covenants of Gem outlined herein in a transaction contemplated by Section 6.1;

       

      (iii)        as may be necessary or appropriate to
            ensure that CVRs are not subject to registration under the U.S. Securities Act of 1933, as amended, or the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations made thereunder, or any applicable state securities or
            “blue sky” laws;

       

      (iv)        as may be necessary or appropriate to
            ensure that Gem is not required to produce a prospectus or an admission document in order to comply with applicable Law;

       

      (v)         to cancel CVRs (i) in the event that
            any Holder has abandoned its rights in accordance with Section 2.6, or (ii) following a transfer of such CVRs to Gem or its Affiliates in accordance with Section 2.2 or Section 2.3; or

       

      (vi)        as may be necessary or appropriate to
            ensure that Gem complies with applicable Law.

       

      (b) Promptly after the execution by Gem of any amendment pursuant to this Section 5.1, Gem will (or will cause the Rights Agent to) notify the Holders in general terms of
        the substance of such amendment in accordance with Section 7.2.

       

      Section 5.2          Effect of Amendments.

       

      Upon the execution of any amendment under this Article 5, this Agreement will be
        modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of Gem which states that the proposed
        supplement or amendment is in compliance with the terms of this Section 5, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the
        contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or
        amendment to this Agreement shall be effective unless duly executed by the Rights Agent.

       

      
        
          

      

      ARTICLE 6

      CONSOLIDATION, MERGER, SALE OR CONVEYANCE

       

      Section 6.1          Gem May Not Consolidate, Etc. Gem shall not consolidate with or merge into any other Person or convey, transfer or lease its properties and assets substantially as an entirety to any Person or transfer
            all or substantially all of its business to any Person, unless:

       

      (a)          the Person formed by such consolidation
            or into which Gem is merged, the Person that acquires the properties and assets of Gem substantially as an entirety or the Person that acquires by conveyance or transfer, or that leases, the Gem substantially as an entirety (the “Surviving Person”) shall expressly assume payment of amounts on all CVRs and the performance of every duty and covenant of this Agreement on the part of Gem to be performed or observed;
            and

       

      (b)          Gem has delivered to the Rights Agent an
            Officer’s Certificate, stating that such consolidation, merger, conveyance, transfer or lease complies with this Article 6 and that all conditions precedent herein provided for
            relating to such transaction have been complied with.

       

      Section 6.2          Successor Substituted.

       

      Upon any consolidation of or merger by Gem with or into any other Person, or any conveyance, transfer or lease of the properties and assets
        substantially as an entirety to any Person in accordance with Section 6.1, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, and
        shall assume all of the obligations of Gem under this Agreement with the same effect as if the Surviving Person had been named as Gem herein.

       

      ARTICLE 7

      MISCELLANEOUS

       

      Section 7.1          Notices to Rights Agent and to Gem.

       

      All notices, requests and other communications (each, a “Notice”) to any party hereunder
        shall be in writing. Such Notice shall be deemed given (a) on the date of delivery, if delivered in person, by Fedex or other internationally recognized overnight courier service or, (except with respect to any Person other than the Rights Agent),
        by e-mail (upon confirmation of receipt) prior to 5:00 p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party or (b) on the first Business Day following the
        date of dispatch, if delivered by FedEx or by other internationally recognized overnight courier service (upon proof of delivery), addressed as follows:

       

      if to the Rights Agent, to:

       

      Continental Stock Transfer and Trust Company

       1 State Street, 30th Floor

       New York NY 10004

      Attn: Compliance

      

      

      
        
          

      

      if to Gem, to:

       

      Gemini Therapeutics, Inc.

      297 Boston Post Road #248

      Wayland, MA 01778

      Attention: CEO

      

      

      or such other address or facsimile number as such party may hereafter specify for the purpose by notice to the other parties hereto.

       

      Section 7.2          Notice to Holders.

       

      All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage
        prepaid, to each Holder at such Holder’s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of
        mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders.

       

      Section 7.3          Entire Agreement.

       

      As between Gem and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this
        Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement.

       

      Section 7.4          Merger or Consolidation or Change of Name of Rights Agent.

       

      Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any
        merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the
        successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent
        under the provisions of Section 3.3. The purchase of the Rights Agent’s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for
        purposes of this Section 7.4.

       

      
        
          

      

      
        Section 7.5          Successors and Assigns.

      

       

      

      This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, Gem and the Rights Agent and their
        respective successors and assigns. Except for assignments pursuant to Section 7.4, the Rights Agent may not assign this Agreement without Gem’s prior written consent. Gem or an Assignee
        may not otherwise assign this Agreement without the prior consent of the Majority of Holders. Any attempted assignment of this Agreement in violation of this Section 7.5 will be void ab initio and of no effect.

       

      Section 7.6          Benefits of Agreement; Action by Acting Holders.

       

      Nothing in this Agreement, express or implied, will give to any Person (other than Gem, the Rights Agent, the Holders and their respective permitted
        successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Gem, the Rights
        Agent, the Holders and their permitted successors and assigns. The Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Acting Holders and/or Acting Holders,
        in accordance with this agreement and as the case may be, will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this
        Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights.

       

      Section 7.7          Governing Law.

       

      This Agreement will be governed by, and construed in accordance with, the laws of the State of New York without regard to the conflicts of law rules of
        such state; provided, that, the CVRs will be governed by, and construed in accordance with, the laws of the State of Delaware without regard to the conflicts of law rules of such state.

       

      Section 7.8          Jurisdiction.

       

      In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated
        hereby, each of the parties hereto: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware, County of New Castle, or, if under applicable Law exclusive
        jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively
        in accordance with clause (a) of this Section 7.8; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are
        an inconvenient forum or do not have jurisdiction over any Party; and (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with Section 7.1 or Section 7.2 of this Agreement.

       

      
        
          

      

      
        Section 7.9          WAIVER OF JURY TRIAL.

         

            

      

      EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
        RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN
        THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
        AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.9.

       

      Section 7.10         Severability Clause.

       

      In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason
        determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void
        or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this
        Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible;
        provided, however, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Gem.

       

      Section 7.11         Counterparts; Effectiveness.

       

      This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto
        and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original.
        This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement
        will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication).

       

      Section 7.12         Termination.

       

      This Agreement will automatically terminate and be of no further force or effect and, except as provided in Section 3.2, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor, upon the expiration of the CVR Period. The termination of this Agreement
        will not affect or limit the right of Holders to receive the CVR Payments under Section 2.4 to the extent earned prior to the termination of this Agreement, and the provisions applicable
        thereto will survive the expiration or termination of this Agreement.

       

      

      
        
          

      

      Section 7.13         Force Majeure.

       

      Notwithstanding anything to the contrary contained herein, none of the Rights Agent, Gem or any of its Subsidiaries (except as it relates to the
        obligations of the Company under Article 3) will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts of God, pandemics (including COVID-19), terrorist acts, shortage of supply,
        breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest.

       

      Section 7.14          Construction.

       

      (a)          For purposes of this Agreement, whenever
            the context requires: singular terms will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will
            include the masculine and feminine genders.

       

      (b)          As used in this Agreement, the words
            “include” and “including,” and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.”

       

      (c)          The headings contained in this Agreement
            are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement.

       

      (d)          Any reference in this Agreement to a
            date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto and Gem have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity
            or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and Gem and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of
            any provision of this Agreement.

       

      (e)          All references herein to “$” are to
            United States Dollars.

       

      [Remainder of page intentionally left blank]

       

      
        
          

      

      IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the day and year first above written.

       

      	

            	
              Gemini Therapeutics, Inc.

            
	

            	

            
	

            	
              By:

            
	

            	
              Name:

            
	

            	
              Title:

            
	

            	

            
	

            	
              Continental Stock Transfer and Trust Company

            
	

            	

            
	

            	
              By:

            
	

            	
              Name:

            
	

            	
              Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]